Sign in
CompletedPhase 2

A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)

Key facts

Who runs it
Aldeyra Therapeutics, Inc.
Where
Bradenton, Dallas, Houston, Richmond, San Antonio, and Tampa, United StatesSee the 6 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
4 people enrolled
Started
4 Nov 2024
Ended
18 Jun 2025
Type of study
Interventional, 2 groups
Treatments tested
  • ADX-629
Record updated
3 June 2026

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adult ≥ 21 years old on the day of signing the informed consent form
  • Clinical diagnosis of alcoholic hepatitis, based on clinical features and laboratory testing, confirmed by the Investigator at screening
  • Agreement to abstain from alcohol and utilize resources to cease at-risk behaviors during the trial, including addiction/alcohol abuse treatment
  • Ability and willingness to swallow tablets
  • Willingness to provide signed informed consent, prior to any trial-related procedures and willingness to comply with the trial procedures and requirements

Who cannot take part

  • Current or recent enrollment in another interventional trial in the 30 days prior to screening
  • Pregnant, intending to become pregnant (or father a child), or breastfeeding

Where in United States

  • Synergry HealthcareBradenton, United States
  • The Liver Institute at Methodist Dallas Medical CenterDallas, United States
  • UDL Clinical Research, LLCHouston, United States
  • Bon Secours Liver Institute of Newport NewsRichmond, United States
  • Methodist Specialty and Transplant HospitalSan Antonio, United States
  • Florida Health Sciences Center/Tampa General Hospital/USFTampa, United States

About the trial

What the trial wants to find out

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)

The 2 groups in the trial

  • ADX-629 (125 mg twice daily)Treatment being tested

    Treatment: ADX-629

  • ADX-629 (250 mg twice daily)Treatment being tested

    Treatment: ADX-629

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Moderate Alcohol Associated Hepatitis
Record updated
3 June 2026